Sermorelin is a 29-aa GHRH analogue that pushes your own pituitary to release GH, instead of replacing it. Exo HGH bypasses the gland and dumps a fixed supraphysiological dose. Sermorelin works upstream: it binds GHRH receptors on somatotrophs in the anterior pituitary, and the gland fires its own GH in pulses that look like normal physiology.
Key Takeaways
- —Sermorelin pushed serum IGF-1 up 117% over baseline across 20 weeks in a controlled trial (Vittone et al., JCEM, 1997) — a real, clinically meaningful jump without ever pinning exo HGH.
- —FDA approved sermorelin (Geref) in 1997 for pediatric GHD. EMD Serono pulled it in 2008 for manufacturing economics, not safety. The 2013 Federal Register spells this out plainly.
- —The pituitary's negative feedback loop stays intact. Once GH climbs high enough, somatostatin kicks in and dampens further release — a built-in ceiling that exo HGH simply doesn't have.
- —US legal status: legal as a 503A compounded prescription, FDA Bulks List Category 1 (highest tier). This is the rare GHRH peptide you can get through a real pharmacy, not just gray market.
Sermorelin is the active N-terminal 29-aa fragment of endogenous GHRH(1–44). The first 29 residues do all the work — they bind and activate the GHRH receptor (GHRHR) at full efficacy, and the remaining 15 residues add nothing measurable (Guillemin et al., Science, 1982). Once it binds GHRHR on anterior pituitary somatotrophs, you get a Gs-protein/adenylyl cyclase/cAMP cascade, and the gland releases GH in discrete pulses.
From there, the GH–IGF-1 axis takes over. GH hits the liver, binds GHR, and the liver pumps out IGF-1. IGF-1 then drives the anabolic, lipolytic, and tissue-repair effects you actually feel — muscle, bone, skin, connective tissue.
The key piece: this whole route keeps the hypothalamic–pituitary feedback loop alive. When GH and IGF-1 climb, the hypothalamus releases somatostatin, which puts the brakes on further pituitary GH output. The gland responds proportionally to the signal it's getting. Exo HGH skips all of this — somatostatin never gets the memo about the dose you just pinned.
That feedback preservation isn't just a safety feature, it's a ceiling. Sermorelin can't push GH higher than what your pituitary is capable of producing on a given night. The dose–response curve self-limits at the top. That's the real differentiator from supraphysiological exo HGH protocols, and it's why people running sermorelin describe a 1.5–2x bump in overnight GH pulses, not the 10x you'd see on exo HGH.
The cleanest published sermorelin trial is Vittone et al., Metabolism, 1997 — double-blind, placebo-controlled. Healthy men, ages 60–75, ran sermorelin (2 mg subq pin nightly) or placebo for 20 weeks. Parallel work by Khorram et al., JCEM, 1997 reported similar IGF-1 responses in older adults given GHRH(1-29).
20-week primary outcomes:
A follow-up looked at how durable the effect was, and IGF-1 elevations hung around for several weeks after stopping — consistent with a trained pituitary axis, not just pharmacological replacement. Earlier GHRH(1-29) work showed the pituitary responds well across age groups (Walker et al., Clinical Endocrinology, 1990), and Corpas et al., JCEM, 1992 documented sustained IGF-1 elevation in older men running GHRH(1-29) for two weeks.
In a 20-week double-blind, placebo-controlled trial (Vittone et al., JCEM 1997), sermorelin at 2 mg nightly subq pin elevated serum IGF-1 by 117% from baseline in healthy older men aged 60–75, with concomitant 7.4% reduction in body fat mass and no serious adverse events recorded.
The IGF-1 gap between sermorelin (+117%) and exo HGH (+150%) is real but tighter than people assume. Sermorelin actually beat HGH on body fat in the Vittone data (7.4% vs ~5.0% from comparable HGH protocols) — likely because physiological pulsatility lights up lipolytic signalling better than continuous supraphysiological exposure.
Sermorelin acetate was approved by the FDA in 1997 under the brand name Geref (EMD Serono) for treating GH deficiency in kids with growth failure. The approval rested on multiple controlled trials showing consistent IGF-1 elevation and growth velocity gains (Chapman et al., JCEM, 1997, which also documented synergistic GH release when sermorelin/GHRH(1-29) was stacked with GHRP-6).
In 2008, EMD Serono voluntarily pulled Geref from the US market. Online sources keep mischaracterising this as a safety withdrawal. The actual record is unambiguous: the 2013 Federal Register (78 FR 46000) lists sermorelin acetate as a drug that was NOT withdrawn for safety or efficacy reasons. The withdrawal came down to manufacturing economics and portfolio reshuffling — Serono dropped it as a commercial product, that's it.
The FDA's 2013 Federal Register (78 FR 46000) explicitly classified sermorelin acetate as not withdrawn from the US market for safety or efficacy reasons. The voluntary 2008 withdrawal by EMD Serono was a manufacturing and commercial decision, preserving sermorelin's legal path for compounded formulations under Section 503A of the Federal Food, Drug, and Cosmetic Act.
This regulatory history matters in practice. Because the FDA didn't tag the withdrawal as safety-related, sermorelin stays eligible for compounding by licensed 503A pharmacies. It currently sits on the FDA's Bulks List for 503A compounding as a Category 1 compound — meaning there's enough evidence of safety and effectiveness to support compounding use, the highest tier on offer.
Current US legal status:
| Channel | Status |
|---|---|
| FDA-approved commercial product | Withdrawn 2008 (Geref no longer marketed) |
| 503A compounded (Category 1) | Legal — requires licensed prescriber and 503A pharmacy |
| Over-the-counter | Not legal |
| Research use | Available as research-grade peptide (not for human use outside clinical settings) |
Sermorelin has a short plasma half-life of about 8–20 minutes after a subq pin. That fast clearance is one reason the compound was designed for once-nightly dosing — the timing rides the natural nocturnal GH pulse that peaks in the first two hours of sleep.
The short half-life isn't a bug, it's a feature. Because sermorelin clears quickly, each pin triggers a discrete pulsatile GH release, instead of producing sustained GH elevation. That pulsatile pattern looks a lot more like endogenous GH physiology than the continuous flat-line you get from exo HGH.
Pulsatile GH isn't "more natural" in some hand-wavy sense — it's mechanistically different. GH receptor signalling responds differently to pulsatile vs continuous exposure. The JAK2–STAT5 pathway, which runs hepatic IGF-1 production, shows stronger activation with pulsatile GH delivery than with continuous infusion in preclinical work. The dosing pattern itself — not just the total dose — probably drives part of sermorelin's clinical efficacy.
The practical takeaway: a single nightly subq pin about 30–60 minutes before sleep is the standard protocol, and that timing isn't arbitrary. It lines up with the window when somatotroph responsiveness is naturally high and somatostatin tone is low.
IGF-1 elevation on sermorelin isn't immediate. The Vittone data and follow-on clinical case series suggest this rough response curve:
The curve is non-linear. Roughly 20% of the total response shows up in the first four weeks; the final plateau lands gradually between weeks 16 and 20. This has practical consequences: blood-draw timing for IGF-1 testing matters, and a four-week lab will heavily underestimate the full response. Anyone pulling labs at four weeks and concluding "sermorelin isn't working" is reading an incomplete dataset.
Published clinical dosing and 503A compounding pharmacy protocols converge on this framework for adult wellness or age-related GH decline research:
| Parameter | Standard Range | Notes |
|---|---|---|
| Dose | 0.2 – 0.3 mg (200–300 mcg) nightly | Vittone used 2 mg — way higher than current standard; compounding protocols typically run lower |
| Route | Subcutaneous injection | Antecubital, abdominal, or thigh fat |
| Timing | 30–60 min before sleep | Aligns with natural nocturnal GH pulse window |
| Reconstitution | Bacteriostatic water | 1–2 mL per 3–6 mg vial depending on concentration |
| Cycle length | 12–26 weeks | Most data comes from 20-week protocols |
| IGF-1 monitoring | Baseline, then weeks 8–12 | Avoid drawing too early |
Reco example: 3 mg vial + 1.5 mL BAC water = 2 mg/mL concentration. A 0.2 mg dose = 0.1 mL draw = 10 IU on a 100-unit insulin syringe.
The Vittone protocol ran 2 mg nightly, but current 503A compounding pharmacy protocols typically use lower doses (0.2–0.3 mg). The reasoning: lower physiological doses look sufficient to drive meaningful IGF-1 elevation while keeping side-effect burden minimal.
The sermorelin vs recombinant human growth hormone (rhHGH) comparison is one of the most-searched topics in this space. The table below lays out the key mechanistic and clinical differences:
| Parameter | Sermorelin | Exogenous rhHGH |
|---|---|---|
| Mechanism | Stimulates pituitary GHRH receptors | Direct GH replacement |
| GH pattern | Pulsatile (physiological) | Continuous (supraphysiological) |
| Pituitary involvement | Yes — gland remains active | No — gland is bypassed |
| Somatostatin feedback | Preserved | Not triggered by exogenous dose |
| IGF-1 elevation | ~117% at 20 weeks (Vittone) | ~150%+ (dose-dependent) |
| Body fat reduction | ~7.4% at 20 weeks | ~5.0% (comparable data sets) |
| Pituitary atrophy risk | Low — gland continues working | Higher — gland may downregulate |
| Regulatory status (US) | Legal compounded (503A Cat. 1) | Prescribing for non-approved indications carries higher regulatory scrutiny |
| Overdose self-limiting | Yes — somatostatin feedback ceiling | No |
The headline favours exo HGH on raw IGF-1 elevation (~150% vs 117%), a range anchored in the landmark trial (Rudman et al., NEJM, 1990). But that framing misses two things. First, the body fat comparison flips — sermorelin appears to produce comparable or better fat loss in the available datasets, possibly because pulsatile GH kinetics keep lipolytic receptors more sensitive. Second, the risk profile diverges meaningfully: sermorelin's self-limiting feedback ceiling means it can't push the sustained supraphysiological GH that drives the classic exo HGH side effects (fluid retention, insulin resistance, carpal tunnel, potential long-bone overgrowth). The honest read: 1.5–2x bump in overnight GH pulses on sermorelin, not 10x like exo HGH.
Sermorelin produces a pulsatile, physiological GH release pattern by binding GHRH receptors in the anterior pituitary, preserving negative somatostatin feedback. Exogenous recombinant HGH bypasses the pituitary entirely and does not trigger somatostatin inhibition, producing continuous GH elevation. This mechanistic difference — pulsatile vs. continuous GH — may explain why sermorelin's body fat reduction (7.4%) rivals or exceeds HGH outcomes in comparable-population studies despite lower absolute IGF-1 elevation.
The published adverse event profile from the Vittone trial and 503A compounding clinical literature is notably modest:
What sermorelin does NOT cause (mechanistically, at physiological doses): the fluid retention, insulin resistance, and joint pain people associate with exo HGH. Those are dose-related consequences of supraphysiological GH exposure — a state sermorelin's feedback ceiling largely prevents.
The sermorelin research profile on Next Pep covers the full 29-aa GHRH analogue mechanism, the Vittone 1997 IGF-1 data, the FDA approval/withdrawal history, and the 503A Category 1 compounding pathway — everything you need to walk into a telehealth consultation already informed. The Next Pep peptide library covers the complete GH-axis secretagogue class in one place.
Use the comparison tool to put sermorelin alongside ipamorelin, CJC-1295, or exo HGH — comparing mechanism, half-life, human trial data, and regulatory status side by side. If you're calculating a sermorelin protocol, the dosing calculator handles the reco math: enter your vial concentration and target dose and it returns exact draw volume in mL and syringe units. Next Pep is the neutral, non-commercial foundation — before you talk to any provider or evaluate any pharmacy.
Yes, with a prescription. Sermorelin sits on the FDA's 503A Bulks List as a Category 1 compound — meaning licensed 503A compounding pharmacies can legally compound it with a valid prescription from a licensed prescriber. The FDA's 2013 Federal Register explicitly confirmed the 2008 Geref market withdrawal was NOT for safety or efficacy reasons, which preserves sermorelin's legal compounding pathway.
IGF-1 elevation builds gradually. In the Vittone et al. controlled trial, the full 117% increase developed over 20 weeks. Roughly 25% of the final response is visible at week 4, about 50% at week 8, and 70–80% by week 12. Labs drawn too early (4 weeks) heavily underestimate the compound's efficacy. Most protocols recommend first monitoring labs at 8–12 weeks.
No — sermorelin actively engages the pituitary instead of bypassing it. The GHRH receptor signalling required for sermorelin's activity keeps somatotrophs working, and somatostatin feedback prevents receptor downregulation from overstimulation. This is the inverse of exo HGH, which can drive pituitary GH production down through long-term negative feedback.
Both are GHRH analogues that stimulate pituitary GH release, but CJC-1295 is structurally modified with a drug-affinity complex (DAC) that stretches its half-life to 6–8 days (vs 8–20 minutes for sermorelin). That means CJC-1295 produces sustained GHRH receptor stimulation rather than discrete pulsatile activation. Some people stack CJC-1295 with ipamorelin (a GHRP) for additive GH stimulation; sermorelin typically gets used as a standalone GHRH agent.
Yes — sermorelin and ipamorelin hit different receptor classes (GHRHR vs GHS-R1a) and the effects stack additively. Sermorelin drives the GHRH pathway; ipa drives the ghrelin pathway through a separate mechanism. Combined protocols show up in some clinical compounding contexts, though published data for the specific sermorelin + ipa combo is thinner than the CJC-1295 + ipamorelin stack, which has more human trial data.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.